Search Results

Download scoring documents for this measure. BACK FACIT-Fatigue Scoring Downloads Download DOC

View all available languages for this measure. BACK PROMIS Pool v1.0 - Dyspnea Task Avoidance Languages English

FACT-CTCL Functional Assessment of Cancer Therapy - Cutaneous T-cell Lymphoma For patients with cutaneous lymphoma LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-CTCL measure: MEASURE NAME: Functional Assessment of Cancer Therapy - Cutaneous T-cell Lymphoma (FACT-CTCL) VERSION: 4 NUMBER OF ITEMS: 46 PATIENT POPULATION: Cutaneous lymphoma patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, CTCL Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. RELATED MEASURES: FACT-Lym , NFLymSI-18 , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-CTCL can be obtained by registering for permission. Users are not permitted to translate the FACT-CTCL without permission from FACIT.org. Permission from FACIT.org to translate the FACT-CTCL may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Lym Functional Assessment of Cancer Therapy – Lymphoma LEARN MORE NFLymSI-18 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index - 18 Item Version LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

Download this measure in English. BACK FACIT-Pal English Downloads Download PDF Download DOC

View all available languages for this measure. BACK FCSI Languages Afrikaans Arabic Bengali Bulgarian Chinese - Simplified Chinese - Traditional Croatian Czech Dutch English Estonian Finnish French Georgian German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Lithuanian Malay Malayalam Marathi Polish Portuguese Punjabi Russian Serbian Slovak Spanish Swedish Tamil Telugu Thai Turkish Ukrainian Vietnamese

Download scoring documents for this measure. BACK FACT-MBIS Scoring Downloads Download DOC

FACIT-AD Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort For patients with Abdominal symptoms LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACIT-AD measure: MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort (FACIT-AD) VERSION: 4 NUMBER OF ITEMS: 30 PATIENT POPULATION: Cancer patients 18 years and older with abdominal discomfort RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Abdominal Discomfort Subscale TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI possible. RELATED MEASURES: FACIT-D , FACT-Ga , FACIT-AI DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-AD can be obtained by registering for permission. Users are not permitted to translate the FACIT-AD without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-AD may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Wenzel, L., Huang, H., Armstrong, D., Walker, J., & Cella, D. Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2007; 25(4): 437-443. doi: 10.1200 /JCO.2006.07.3494. Wenzel, L., Huang, H., Cella, D., Walker, J., & Armstrong, D. Validation of FACT/COG-AD subscale for ovarian cancer related abdominal discomfort: A Gynecologic Group Study. Gynecologic Oncology 2008. 110 (1): 60-64. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., & Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., & Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-D Functional Assessment of Chronic Illness Therapy – Diarrhea LEARN MORE FACT-Ga Functional Assessment of Cancer Therapy – Gastric LEARN MORE FACIT-AI Functional Assessment of Chronic Illness Therapy - Ascites Index LEARN MORE

FACT-BRM Functional Assessment of Cancer Therapy - Biologic Response Modifiers For patients receiving Biologic Response Modifiers LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Biological Response Modifier (FACT-BRM) measures quality of life in cancer patients who are receiving treatment with biologic response modifiers. Using the FACT-G as a base, 17 additional items related to symptoms common to interferon and retinoid therapy were developed. Data collected at baseline (n = 191) and week 2 (n = 168) in a randomized trial of interferon ±13-cis-retinoic acid in advanced renal cell carcinoma patients were used to validate the instrument. Using a combined empirical and conceptual approach, the 17 items were reduced to 13 items consisting of two subscales: ‘BRM-physical’ (7 items) and ‘BRM-mental’ (6 items). Internal consistency of the trial outcome index (TOI) combining physical well-being, functional well-being and the BRM subscales, was 0.91 for baseline assessments and 0.92 for week 2. Discriminant validity was demonstrated for the TOI by its ability to differentiate among prognostic risk groups, and for the total FACT-G, TOI and total FACT–BRM scores by their ability to distinguish between groups differing in performance, response and toxicity status. MEASURE NAME: Functional Assessment of Cancer Therapy - Biologic Response Modifiers (FACT-BRM) VERSION: 4 NUMBER OF ITEMS: 40 PATIENT POPULATION: Cancer patients 18 years and older receiving treatment with biological response modifiers RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, BRM-Physical, BRM-Mental TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACT-BMT , FACT/GOG-NTX , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-BRM can be obtained by registering for permission. Users are not permitted to translate the FACT-BRM without permission from FACIT.org. Permission from FACIT.org to translate the FACT-BRM may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bacik, J., Mazumdar, M., Murphy, B., Fairclough, D., Eremenco, S., Mariani, T., Motzer, R., & Cella, D. The functional assessment of cancer therapy-BRM (FACT-BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers. Quality of Life Research 2004; 13(1): 137-154. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-BMT Functional Assessment of Cancer Therapy - Bone Marrow Transplantation LEARN MORE FACT/GOG-NTX Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

FACIT Item GP5 Functional Assessment of Chronic Illness Therapy - Item GP5 Item GP5 from the FACIT Measurement System LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The single FACT-G item, GP5, “I am bothered by side effects of treatment,” is a summary measure of the overall impact of treatment toxicity, based upon its association with the number and degree of adverse events in clinical trials. The single item has demonstrated a significant relationship to overall quality of life as indicated by ability to enjoy life. It has been aligned with the current Food and Drug Administration interest in evaluating the patient’s perspective on treatment of adverse events, and it has been shown to be significantly associated with clinician-reported adverse events. MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Item GP5 VERSION: 4 NUMBER OF ITEMS: 1 PATIENT POPULATION: Patients 18 years and older receiving treatment RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: None TIME FOR COMPLETION: Less than 1 minute SCORING: Single score RELATED MEASURES: FACT-G , FACT-G7 , FANLTC DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of item GP5 can be obtained by registering for permission. Users are not permitted to translate item GP5 without permission from FACIT.org. Permission from FACIT.org to translate item GP5 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Pearman T.P., Beaumont J.L., Mroczek D., O'Connor M., Cella D. Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. Cancer 2018 Mar 1;124(5):991-997. doi: 10.1002/cncr.31133. Epub 2017 Nov 13. PMID: 29131323; PMCID: PMC5892190. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Lloyd S., Linn E., Bonomi A., Silberman M., Yellen S.B., Winicour P., Brannon J., Eckberg K., Purl S., Blendowski C., Goodman M., Barnicle M., Stewart I., McHale M., Bonomi P., Kaplan E., Taylor S., Thomas C., Harris J. The Functional Assessment of Cancer Therapy (FACT) Scale: Development and validation of the general measure. Journal of Clinical Oncology 1993; 11(3): 570-579. Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Juárez Soto Á, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN; TITAN investigators. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol . 2019 Nov;20(11):1518-1530. doi: 10.1016/S1470-2045(19)30620-5. Epub 2019 Sep 29. PMID: 31578173. Arizmendi C, Zhu Y, Khan M, Gable J, Reeve BB, King-Kallimanis B, Bell J. The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments. Qual Life Res . 2024 Oct;33(10):2869-2880. doi: 10.1007/s11136-024-03740-x. Epub 2024 Jul 24. PMID: 39046616; PMCID: PMC11452438. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Brucker P.S., Yost K., Cashy J., Webster K., Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy – General (FACT-G). Evaluation & the Health Professions 2005; 28(2): 192-211. Cella D, Escudier B, Rini B, Chen C, Bhattacharyya H, Tarazi J, Rosbrook B, Kim S, Motzer R. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. British Journal of Cancer 2013; 108: 1571-78. Cella D., Hahn E., Dineen K. Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Quality of Life Research 2002; 11(3): 207-21. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Gharzai LA, Mierzwa ML, Stepan KO, Cella D, Peipert JD. Validity of a single-item indicator of treatment side effect bother in patients with head and neck cancer. Support Care Cancer . 2024 Aug 6;32(9):575. doi: 10.1007/s00520-024-08775-x. PMID: 39107440. Griffiths P, Peipert JD, Leith A, Rider A, Morgan L, Cella D, Cocks K. Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients. Support Care Cancer. 2022 Apr;30(4):3613-3623. doi: 10.1007/s00520-022-06802-3. Epub 2022 Jan 14. PMID: 35031830; PMCID: PMC8857159. Hahn E, Glendenning A, Sorensen M, Hudgense S, Druker B, Guilhot F, Larson R, O’Brien S, Dobrez D, Hensley M, Cella D. Quality of life in patients with newly diagnosed chronic myeloid leukemia on imatinib versus interferon plus low-dose ARA-C: results from the IRIS study. J Clin Oncol 2003; 21(11): 2138-2146. O'Connell NS, Zhao F, Lee JW, Ip EH, Peipert JD, Graham N, Smith ML, Gareen IF, Carlos RC, Obeng-Gyasi S, Sparano JA, Shanafelt TD, Thomas ML, Cella D, Wagner LI, Gray R. Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial. J Clin Oncol . 2024 Jan 20;42(3):266-272. doi: 10.1200/JCO.23.00377. Epub 2023 Oct 6. PMID: 37801678; PMCID: PMC10824381. Pearman T., Yanez B., Peipert J., Wortman K., Beaumont J., Cella D. Ambulatory cancer and US general population reference values and cutoff scores for the Functional Assessment of Cancer Therapy. Cancer 2014: 2902-2909. Peipert JD, Zhao F, Lee J, et al. Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma. JAMA Netw Open . 2024;7(3):e243854. doi:10.1001/jamanetworkopen.2024.3854 Peipert JD, Zhao F, Lee JW, Shen SE, Ip E, O'Connell N, Carlos RC, Graham N, Smith ML, Gareen IF, Raper PJ, Weiss M, Kumar SK, Rajkumar SV, Cella D, Gray R, Wagner LI. Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma. JAMA Netw Open. 2024 Mar 4;7(3):e243854. doi: 10.1001/jamanetworkopen.2024.3854. PMID: 38536173; PMCID: PMC10973895. Peipert JD, Shaunfield S, Kaiser K, Moreno PI, Fox RS, Kircher S, Mohindra N, Ip E, Zhao F, Wagner L, Cella D. How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability? Support Care Cancer . 2022 Dec 16;31(1):37. doi: 10.1007/s00520-022-07484-7. Erratum in: Support Care Cancer . 2023 Jul 24;31(8):489. doi: 10.1007/s00520-023-07953-7. PMID: 36525100; PMCID: PMC10356672. Peipert J.D., Cella D. Bifactor analysis confirmation of the factorial structure of the Functional Assessment of Cancer Therapy – General (FACT-G). Psycho-Oncology 2019; 28: 1149-1152. Regnault, A., Bunod, L., Loubert, A. et al. Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer. J Patient Rep Outcomes 8, 149 (2024). https://doi.org/10.1186/s41687-024-00823-8. Roydhouse JK, King-Kallimanis BL, Roy P, Weinstock C, Krol D, Daniels SR, Suzman DL, Beaver JA, Kluetz PG. Exploration of baseline patient-reported side effect bother from cancer therapy. Clin Trials . 2020 Jun;17(3):332-337. doi: 10.1177/1740774520910389. Epub 2020 Mar 10. PMID: 32153216. Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol . 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10. PMID: 30213449. Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevich DA, Sledge GW, Cella D. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast Cancer Res Treat . 2018 Jun;169(3):537-548. doi: 10.1007/s10549-018-4713-2. Epub 2018 Feb 17. PMID: 29455298; PMCID: PMC6092930. Wagner L, Zhao F, Chapman J, Cella D, Shepherd L, Sledge G, Goss P. Patient-reported predictors of early treatment discontinuation: NCIC JMA.27/E1Z03 Quality of life study of postmenopausal women with primary breast cancer randomized to exemestane or anastrozole. Cancer Res 2011; 71(24S): Abstract S6-2. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-G Functional Assessment of Cancer Therapy - General LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy - General - 7 Item Version LEARN MORE FANLTC Functional Assessment of Non-Life Threatening Conditions LEARN MORE

View all available languages for this measure. BACK DVT-LSI Languages English

View all available languages for this measure. BACK FACT-B Languages Afrikaans Arabic Armenian Bengali Bosnian Bulgarian Burmese Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Farsi Finnish French German Greek Gujarati Haitian Creole Hebrew Hindi Hungarian Indonesian Italian Japanese Kannada Korean Latvian Lithuanian Macedonian Malay Malayalam Maltese Marathi Norwegian Odia Polish Portuguese Punjabi Romanian Russian Sepedi Serbian Slovak Slovene Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Wolof Xhosa Zulu

View all available languages for this measure. BACK FACT-EGFRI-18 Languages Arabic Bulgarian Cebuano Chinese - Simplified Chinese - Traditional Czech Dutch English French Georgian German Greek Hebrew Hungarian Italian Japanese Korean Latvian Malay Polish Portuguese Romanian Russian Serbian Spanish Tagalog Tamil Thai Turkish Ukrainian Vietnamese